Results 211 to 220 of about 39,420,205 (310)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

A disease-agnostic approach to ensemble learning for infectious disease forecasting. [PDF]

open access: yesNat Commun
Murph AC   +5 more
europepmc   +1 more source

Gait Classification Based on Micro-Doppler Effect. [PDF]

open access: yesSensors (Basel)
Chen Y   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy